EN PL
SHORT COMMUNICATION
Not just pain and morning stiffness duration in the daily experience of patients with polymyalgia rheumatica. Does the rheumatologist listen to all patient-reported outcomes?
,
 
 
 
More details
Hide details
1
Azienda Sanitaria Locale Napoli 3 sud, Internal and Geriatric Medicine Department, Rheumatologic Outpatient Clinic Hospital “Mariano Lauro”, Sant’Agnello, Italy
 
2
Azienda Sanitaria Provinciale Catanzaro, Primary Care Department, Fragility Outpatient Clinic, Catanzaro, Italy
 
3
Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Medical Faculty, Adnan Menderes University, Aydın, Turkey
 
 
Submission date: 2021-03-10
 
 
Acceptance date: 2021-04-27
 
 
Online publication date: 2021-05-23
 
 
Publication date: 2021-07-16
 
 
Reumatologia 2021;59(3):200-202
 
KEYWORDS
TOPICS
ABSTRACT
Patient-reported outcomes (PROs) provide a means for patients to communicate with their care teams about their disease. Polymyalgia rheumatica (PMR) is considered to be one of the most common inflammatory rheumatic diseases in older adults. The Visual Analogue Scale (VAS) of pain is the only PRO assessed by the PMR activity score (PMR-AS), which is still the only validated score for monitoring disease activity in patients affected with PMR. Other PROs such as fatigue, sleep disturbances, depressive symptoms, and patient’s perspective related to adverse effects of prednisolone are still unmet needs. This short communication suggests the gerontorheumatological outpatient clinic as an answer.
 
REFERENCES (26)
1.
Manzo C, Camellino D. Polymyalgia rheumatica: diagnostic and therapeutic issues of an apparently straightforward disease. Recenti Prog Med 2017; 108: 221–231, DOI: 10.1701/ 2695.27559 [Article in Italian].
 
2.
Manzo C, Natale M, Traini E. Diagnosis of polymyalgia rheumatica in primary health care: favoring and confounding factors – a cohort study. Reumatologia 2018; 56: 131–139, DOI: 10.5114/reum.2018.76900.
 
3.
Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatic. Ann Rheum Dis 2004; 63: 1279–1283, DOI: 10.1136/ard.2003.011379.
 
4.
Dejaco C, Duftner C, Cimmino MA, et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis 2011; 70: 447–453, DOI: 10.1136/ard.2010.133850.
 
5.
Devauchelle-Pensec V, Saraux L, Berthelot JM, et al. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. Rheumatology (Oxford) 2018; 57, 666–670, DOI: 10.1093/rheumatology/kex477.
 
6.
Shortell SM, Poon BY, Ramsay PP, et al A multilevel analysis of patient engagement and patient-reported outcomes in primary care practices of accountable care organizations. J Gen Intern Med 2017; 32: 640–647, DOI: 10.1007/s11606-016-3980-z.
 
7.
Philpot LM, Barnes SA, Brown RM, et al. Barriers and benefits to the use of patient-reported outcome measures in routine clinical care: a qualitative study. Am J Med Qual 2018; 33: 359–364, DOI: 10.1177/1062860617745986.
 
8.
de Wit MP, Berlo SE, Aanerud GJ, et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis 2011; 70: 722–726, DOI: 10.1136/ard.2010.135129.
 
9.
Mackie SL, Hughes R, Walsh M, et al. “An impediment to living life”: why and how should we measure stiffness in polymyalgia rheumatica? PLoS One 2015; 10: e0126758, DOI: 10.1371/journal.pone.0126758.
 
10.
Muller S, Whittle R, Hider SL, et al. Longitudinal clusters of pain and stiffness in polymyalgia rherheumatic-year results from the PMR Cohort Study. Rheumatology (Oxford) 2020; 59: 1906–1915, DOI: 10.1093/rheumatology/kez533.
 
11.
Matteson EL, Maradit-Kremers H, Cimmino MA, et al. Patient- reported outcomes in polymyalgia reumatica. J Rheumatol 2012; 39: 795–803, DOI: 10.3899/jrheum.110977.
 
12.
Black RJ, Robson JC, Goodman SM, et al. A patient-reported outcome measure for effect of glucocorticoid therapy in adults with inflammatory diseases is needed: report from the OMERACT 2016 special interest group. J Rheumatol 2017; 44: 1754–1758, DOI: 10.3899/jrheum.161083.
 
13.
Mackie SL, Arat S, da Silva J, et al. Polymyalgia Rheumatica (PMR) special interest group at OMERACT 11: outcomes of importance for patients with PMR. J Rheumatol 2014; 41: 819–823, DOI: 10.3899/jrheum.131254.
 
14.
Manzo C, Nizama-Via A, Milckert M, et al. Depression and depressive symptoms in patients with polymyalgia rheumatica: discussion points, grey areas and unmet needs emerging from a systematic review of published literature. Reumatologia 2020; 58: 381–389, DOI: 10.5114/reum.2020.102003.
 
15.
Manzo C, Castagna A. Subjective sleep disturbances at the time of diagnosis in patients with polymyalgia rheumatica and in patients with seronegative elderly-onset rheumatoid arthritis. A pilot study. Reumatologia 2020; 58: 196–201, DOI: 10.5114/reum.2020.98430.
 
16.
Hoon E, Ruediger C, Gill TK, et al. A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis. Open Access Rheumatol 2019; 11: 189–198, DOI: 10.2147/OARRR.S213964.
 
17.
Manzo C, Serra-Mestres J, Castagna A, Isetta M. Behavioral, psychiatric, and cognitive adverse events in older persons treated with glucocorticoids. Medicines (Basel) 2018; 5: 82, DOI: 10.3390/medicines5030082.
 
18.
Twohig H, Mitchell C, Mallen C, et al. “I suddenly felt I’d aged”: a qualitative study of patients experiences of polymyalgia rheumatica (PMR). Patient Educ Couns 2015; 98: 645–650, DOI: 10.1016/j.pec.2014.12.013.
 
19.
Manzo C, Putignano S, Stisi S. Malattie reumatiche e paziente geriatrico: spunti operativi e qualche riflessione per un mondo che sta cambiando. G It Reumatol Clin 2016; 2: 15–27 [Article in Italian].
 
20.
Owen CE, Yates M, Twohig H, et al. Toward a core outcome measurement set for Polymyalgia Rheumatica: report from the OMERACT 2018 special interest group. J Rheumatol 2019; 46: 1360–1364, DOI: 10.3899/jrheum.181050.
 
21.
Duarte C, Ferreira RJ, Mackie SL, et al. Outcome measures in polymyalgia rheumatica: a systematic review. J Rheumatol 2015; 42: 2503–2511, DOI: 10.3899/jrheum.150515.
 
22.
Yates M, Owen CE, Muller S, et al. Feasibility and face validity of outcome measures for use in future studies of polymyalgia rheumatica: an OMERACT study. J Rheumatol 2020; 47: 1379–1384, DOI: 10.3899/jrheum.190575.
 
23.
Prior JA, Muller S, Helliwell T, et al. The association of pain and stiffness with fatigue in incident polymyalgia rheumatica: baseline results from the polymyalgia rheumatica cohort study. Prim Health Care Res Dev 2019; 20: e46, DOI: 10.1017/S1463423619000082.
 
24.
van Lankveld W, Franssen M, Stenger A. Gerontorheumatology: the challenge to meet health-care demands for the elderly with musculoskeletal conditions. Rheumatology (Oxford) 2005; 44: 419–422, DOI: 10.1093/rheumatology/keh555.
 
25.
Manzo C. La polimialgia reumatica: cosa è utile sapere per il geriatra territoriale? Geriatria Extraospedaliera 2009; 7: 9–11 [Article in Italian].
 
26.
Michet CJ Jr, Evans JM, Fleming KC, et al. Common rheumatologic diseases in elderly patients. Mayo Clin Proc 1995; 70: 1205–1214, DOI: 10.4065/70.12.1205.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top